Cystic Fibrosis–Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes

Cystic fibrosis (CF) is a recessive disorder arising from mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is expressed in numerous tissues, with high expression in the airways, small and large intestine, pancreatic and hepatobiliary ducts,...

Full description

Saved in:
Bibliographic Details
Published inDiabetes care Vol. 46; no. 6; pp. 1112 - 1123
Main Authors Putman, Melissa S., Norris, Andrew W., Hull, Rebecca L., Rickels, Michael R., Sussel, Lori, Blackman, Scott M., Chan, Christine L., Ode, Katie Larson, Daley, Tanicia, Stecenko, Arlene A., Moran, Antoinette, Helmick, Meagan J., Cray, Sharon, Alvarez, Jessica A., Stallings, Virginia A., Tuggle, Katherine L., Clancy, John P., Eggerman, Thomas L., Engelhardt, John F., Kelly, Andrea
Format Journal Article
LanguageEnglish
Published United States American Diabetes Association 01.06.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cystic fibrosis (CF) is a recessive disorder arising from mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is expressed in numerous tissues, with high expression in the airways, small and large intestine, pancreatic and hepatobiliary ducts, and male reproductive tract. CFTR loss in these tissues disrupts regulation of salt, bicarbonate, and water balance across their epithelia, resulting in a systemic disorder with progressive organ dysfunction and damage. Pancreatic exocrine damage ultimately manifests as pancreatic exocrine insufficiency that begins as early as infancy. Pancreatic remodeling accompanies this early damage, during which abnormal glucose tolerance can be observed in toddlers. With increasing age, however, insulin secretion defects progress such that CF-related diabetes (CFRD) occurs in 20% of teens and up to half of adults with CF. The relevance of CFRD is highlighted by its association with increased morbidity, mortality, and patient burden. While clinical research on CFRD has greatly assisted in the care of individuals with CFRD, key knowledge gaps on CFRD pathogenesis remain. Furthermore, the wide use of CFTR modulators to restore CFTR activity is changing the CFRD clinical landscape and the field’s understanding of CFRD pathogenesis. For these reasons, the National Institute of Diabetes and Digestive and Kidney Diseases and the Cystic Fibrosis Foundation sponsored a CFRD Scientific Workshop, 23–25 June 2021, to define knowledge gaps and needed research areas. This article describes the findings from this workshop and plots a path for CFRD research that is needed over the next decade.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0149-5992
1935-5548
1935-5548
DOI:10.2337/dc23-0380